Complete financial analysis of Nutriband Inc. (NTRBW) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Nutriband Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Air Arabia PJSC (AIRARABIA.AE) Income Statement Analysis – Financial Results
- Xero Limited (XROLF) Income Statement Analysis – Financial Results
- PT Wismilak Inti Makmur Tbk (WIIM.JK) Income Statement Analysis – Financial Results
- AB SKF (publ) (SKFRY) Income Statement Analysis – Financial Results
- Babcock & Wilcox Enterprises, Inc. (BW-PA) Income Statement Analysis – Financial Results
Nutriband Inc. (NTRBW)
About Nutriband Inc.
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain. The company has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. Nutriband Inc. was incorporated in 2016 and is headquartered in Orlando, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.09M | 2.08M | 1.42M | 943.70K | 370.65K | 245.29K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.22M | 1.33M | 917.84K | 582.38K | 549.11K | 288.30K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 862.11K | 750.41K | 504.31K | 361.32K | -178.46K | -43.02K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 41.34% | 36.08% | 35.46% | 38.29% | -48.15% | -17.54% | 0.00% | 0.00% | 0.00% |
| Research & Development | 1.96M | 982.23K | 411.38K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 4.02M | 2.91M | 0.00 | 0.00 | 0.00 | 143.49K | 4.80K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 45.00K | 0.00 | 0.00 | 0.00 | 7.77K | -4.40K |
| SG&A | 3.77M | 3.92M | 4.02M | 2.96M | 1.79M | 3.29M | 171.95K | 151.26K | 400.00 |
| Other Expenses | 0.00 | 327.33K | 2.18M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 5.73M | 4.90M | 4.43M | 2.96M | 1.79M | 3.29M | 171.95K | 151.26K | 400.00 |
| Cost & Expenses | 6.96M | 6.23M | 5.35M | 3.54M | 2.34M | 3.58M | 171.95K | 151.26K | 400.00 |
| Interest Income | 16.85K | 8.29K | 118.42K | 280.69K | 73.41K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 75.82K | 8.29K | 118.42K | 280.69K | 73.41K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 287.72K | 368.96K | 318.26K | 169.72K | 91.84K | 37.01K | 147.26K | 151.26K | 4.80K |
| EBITDA | -5.12M | -4.11M | -5.74M | -2.48M | -2.56M | -3.29M | -2.67M | 0.00 | -400.00 |
| EBITDA Ratio | -245.61% | -181.71% | -253.96% | -264.42% | -506.69% | -1,343.02% | 0.00% | 0.00% | 0.00% |
| Operating Income | -4.87M | -4.15M | -3.93M | -2.60M | -1.97M | -3.33M | -171.95K | -151.26K | -400.00 |
| Operating Income Ratio | -233.63% | -199.45% | -276.33% | -275.08% | -531.35% | -1,358.11% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -613.39K | -335.62K | -2.25M | -336.88K | -752.19K | 0.00 | -2.50M | 0.00 | 0.00 |
| Income Before Tax | -5.49M | -4.48M | -6.18M | -2.93M | -2.72M | -3.33M | -2.67M | -151.26K | -400.00 |
| Income Before Tax Ratio | -263.04% | -215.59% | -434.28% | -310.78% | -734.29% | -1,358.11% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 327.33K | 2.25M | 280.69K | 73.41K | -124.13K | 2.35M | -151.26K | -4.80K |
| Net Income | -5.49M | -4.81M | -8.42M | -3.21M | -2.80M | -3.33M | -2.67M | -151.26K | -400.00 |
| Net Income Ratio | -263.04% | -231.33% | -592.23% | -340.52% | -754.10% | -1,358.11% | 0.00% | 0.00% | 0.00% |
| EPS | -0.69 | -0.57 | -1.06 | -0.48 | -0.44 | -0.53 | -0.48 | -0.03 | 0.00 |
| EPS Diluted | -0.69 | -0.57 | -1.06 | -0.48 | -0.44 | -0.53 | -0.48 | -0.03 | 0.00 |
| Weighted Avg Shares Out | 7.95M | 8.46M | 7.93M | 6.73M | 6.33M | 6.24M | 5.60M | 6.06M | 6.06M |
| Weighted Avg Shares Out (Dil) | 7.95M | 8.46M | 7.93M | 6.73M | 6.33M | 6.24M | 5.60M | 6.06M | 6.06M |
Nutriband Inc. Quarterly Report Highlights Record Revenue for Q3 up 50.94% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl in 2025
ORLANDO, Fla., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) today reported its financial results for the third quarter ended October 31, 2024.
Nutriband Receives Hong Kong Patent Notice of Publication for Its Aversa™ Abuse Deterrent Transdermal Technology
ORLANDO, Fla., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it has received a Notice of Publication of the Registration and Grant of a Standard...
Nutriband Inc. Issued Full Patent from the Chinese National Intellectual Property Administrant for Its "Abuse and Misuse Deterrent Transdermal System" Application
ORLANDO, FL / ACCESSWIRE / October 31, 2024 / Nutriband (NASDAQ:NTRB)(NASDAQ:NTRBW), has announced that theChinese National Intellectual Property Administrant (CNIPA) has fully issued its patent titled "Abuse and Misuse Deterrent Transdermal System" which is related to the Company's lead technology...
Nutriband Inc Mosquito Repellent Patch Approved by Ministry of Health of Costa Rica
The approved product will be exclusively distributed through Farmavision S.A. throughout Costa Rica ORLANDO, FL / ACCESSWIRE / October 17, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), today announced that it has received approval from the Costa Rica Ministry of Health for...
Join Nutriband's Exclusive Live Investor Webinar and Q&A Session on October 17
ORLANDO, FL / ACCESSWIRE / October 2, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical solutions, is pleased to invite investors to a webinar on October 17, 2024, at 4:15 p.m. ET. The exclusive event, hosted by RedChip...
Nutriband Receives China Patent Notice of Allowance for Its Aversa(TM) Abuse Deterrent Transdermal Technology
Notice of Allowance received from Chinese National Intellectual Property Administration (CNIPA) for the patent application covering its Platform AVERSA™ abuse deterrent transdermal technology Nutriband abuse-deterrent transdermal technology consists of a proprietary aversive agent coating that employs taste aversion to deter...
Nutriband Licenses Bitrex(R) Brand Aversive Agent for Its Lead Product - Aversa(TM) Fentanyl Transdermal Patch
Nutriband signs trademark licensing agreement for Bitrex® brand denatonium benzoate, the most bitter substance in the world, as an aversive agent for its Aversa™ Fentanyl abuse deterrent fentanyl transdermal patch Nutriband abuse-deterrent transdermal technology consists of a proprietary aversive agent...
Nutriband Inc. Authorizes $1M Share Buyback Program
ORLANDO, FL / ACCESSWIRE / September 16, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), has announced a share repurchase program to buy back up to $1,000,000 of its common stock. As of September 16, 2024, the Company had 11,106,185 shares of common...
Nutriband Inc. Quarterly Report Highlights Strong Cash Position, and Strategic Progress Toward NDA Filing for AVERSA Fentanyl in 2025
ORLANDO, FL / ACCESSWIRE / September 4, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) has reported its financial results for the second quarter ended July 31, 2024. The Company reported a strong cash position at quarter end, reinforcing its ability to advance...
Join Nutriband's Exclusive Live Investor Webinar and Q&A Session on July 25
ORLANDO, FL / ACCESSWIRE / July 19, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical solutions, is pleased to invite investors to a webinar on July 25, 2024, at 4:15 p.m. ET. The exclusive event, hosted by RedChip...
Source: https://incomestatements.info
Category: Stock Reports